This Phase I clinical study will assess the safety and pharmacokinetics of the experimental drug J147 in healthy adults. Researchers are investigating the drug as a potential treatment for Alzheimer's disease.wisepoqder J147 powder

Exclusion Criteria
History or evidence of heart, endocrine, blood, immune, gastrointestinal, genital, urinary, or other body system disease
History or evidence of disease or dysfunction in neurological or psychiatric system that is likely to affect study results
Any disorder that would interfere with the absorption, distribution, metabolism, or excretion of drugs
Any concurrent disease or condition that would make the participant unsuitable for study participation
Positive for hepatitis B surface antigen, hepatitis C antibody, or HIV antibodies
Positive test for ethanol (alcohol) or cotinine (tobacco) at screening or admission
Positive urine drug test (e.g., cocaine, amphetamines, barbiturates, opiates, benzodiazepines, cannabinoids) at screening or admission
Is unwilling to avoid consumption of grapefruit, Seville oranges, or other products containing grapefruit or Seville oranges within 14 days of taking the study drug
History of alcohol and/or illicit drug abuse in past year or is unwilling to avoid use of alcohol or alcohol-containing foods, medications, or beverages within 48 hours of admission until discharge from the clinical unit
Has donated blood or blood products within 30 days of first dosing
Requires treatment with any prescription drugs or over-the-counter medications, including vitamins (large doses), dietary supplements, or herbal medications, within 14 days of study medication (acetaminophen 1,000 mg per day and recommended daily doses of vitamins are permitted)
Has received any known liver or kidney clearance altering agents (e.g., erythromycin, cimetidine, barbiturates, phenothiazines, or St. John's wort) within 30 days of study start
Has used an investigational drug within 30 days of screening
Hypersensitivity or allergies to J147, any of its components, or any drug within the same class
Significant abnormal vital signs on physical exam or laboratory results
Is considering or has scheduled any surgical procedure during study participation
Requires a special diet or has a significant food allergy or intolerance (vegetarian diet may be permitted)
Currently enrolled in another clinical study
Evidence of cognitive decline that is greater than expected for participant's age or changes in level of independence in everyday life
Detailed Description
J147 is a synthetic derivative of curcumin, a component of the curry spice turmeric. In this study participants will be randomly assigned to take either the study drug or a placebo in an escalating dose. Doses will first be given to younger participants after an 8-hour fast. Older participants will then receive doses that have been found to be safe in younger participants.

Posted by: shinenewstop at 05:03 PM | No Comments | Add Comment
Post contains 434 words, total size 3 kb.